Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Open Access
- 1 July 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (7), 940-949
- https://doi.org/10.1097/jto.0b013e3181dc211f
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- HIF-1 regulation: not so easy come, easy goTrends in Biochemical Sciences, 2008
- PX‐478, an inhibitor of hypoxia‐inducible factor‐1α, enhances radiosensitivity of prostate carcinoma cellsInternational Journal of Cancer, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockadeMolecular Cancer Therapeutics, 2007
- Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lungEuropean Journal of Cardio-Thoracic Surgery, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- DEC1 (STRA13) protein expression relates to hypoxia‐ inducible factor 1‐alpha and carbonic anhydrase‐9 overexpression in non‐small cell lung cancerThe Journal of Pathology, 2003